|
Age in years, mean (SD)
|
36.5 (13.4)
|
33.1 (12.0)
|
0.0028
|
|
Sex
| | |
0.619
|
|
Male
|
90 (35.7)
|
84 (33.7)
| |
|
Female
|
161 (64.1)
|
165 (66.3)
| |
|
Marital status
| | |
0.962
|
|
Married
|
129 (51.4)
|
131 (52.6)
| |
|
Single
|
101 (40.2)
|
98 (39.4)
| |
|
Children
|
21 (8.4)
|
20 (8.0)
| |
|
CD4, median (IQR)
|
180 (85–310)
|
261.5 (118–452)
|
< 0.001
|
|
CD4
| | |
0.006
|
|
500 and less
|
191 (89.7)
|
155 (79.9)
| |
|
> 500
|
22 (10.3)
|
39 (20.1)
| |
|
First viral load, median (IQR)
|
13,551 (2851–47,095)
|
2298.5 (0–26,508)
|
< 0.001
|
|
Initial regimen
| | |
< 0.001
|
|
Efavirenz-based regimen
|
130 (51.8)
|
187 (75.1)
| |
|
Non-Efavirenz-based regimen
|
121 (48.2)
|
62 (24.9)
| |
|
Current regimen
| | |
< 0.001
|
|
NNRTI
|
42 (16.7)
|
68 (27.3)
| |
|
Protease Inhibitors
|
179 (71.3)
|
135 (54.2)
| |
|
DTG-based regimen
|
30 (12.0)
|
46 (18.5)
| |
|
Regimen switching
| | |
< 0.001
|
|
0
|
73 (29.1)
|
124 (49.8)
| |
|
1
|
174 (69.3)
|
124 (49.8)
| |
|
2
|
4 (1.6)
|
1 (0.4)
| |
|
First detectable viral load, median (IQR)
|
20,782 (20,669–20,847)
|
21,206 (21,017–21,390)
|
< 0.001
|
|
Days on ART, median (IQR)
|
878.5 (395–1471)
|
988.5 (336–1595)
|
0.648
|
